Skip to content
← Full study record

NCT04145700 · MORE INFO

Limitations, agreements, and source contact

CAMPFIRE: A Study of Ramucirumab (LY3009806) in Children and Young Adults With Synovial Sarcoma · Source last updated 2023-09-13

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

certain Agreement
pi Sponsor Employee
false
restriction Type
GT60
restrictive Agreement
true
limitations And Caveats
description
The limitation to this study was the highly varied estimates of the PFS HR and the probability of PFS HR \< 1 due to influence from the matched historical controls whose PFS substantially outperformed PFS from the prospectively randomized control.
point Of Contact
email
ClinicalTrials.gov@lilly.com
organization
Eli Lilly and Company
phone
800-545-5979
title
Chief Medical Officer
Complete source fields
certain Agreement
pi Sponsor Employee
false
restriction Type
GT60
restrictive Agreement
true
limitations And Caveats
description
The limitation to this study was the highly varied estimates of the PFS HR and the probability of PFS HR \< 1 due to influence from the matched historical controls whose PFS substantially outperformed PFS from the prospectively randomized control.
point Of Contact
email
ClinicalTrials.gov@lilly.com
organization
Eli Lilly and Company
phone
800-545-5979
title
Chief Medical Officer

Download exact source JSON → · Snapshot ctgov-results-191f4516d4760045304b24a0

Preserved source evidence · Not medical advice